Harrow Health Inc (HROW)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.09B
Last updated: Nov 17, 2026 at 4:24 PM ET
Harrow Health Inc (HROW) Statistics
Harrow Health (HROW) has a market cap of $1.09B and an enterprise value of $1.32B. Revenue grew 21.28% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 20.66% above the market cap, as debt exceeds cash.
| Market Cap | $1.09B |
|---|---|
| Enterprise Value | $1.32B |
| Latest price (Nov 17, 2026) | $29.52 |
Key Dates
The next earnings report is set for Mar 1, 2027, after the close.
| Next Earnings Date | Mar 1, 2027, after the close |
|---|---|
| Last Earnings Date | Nov 9, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 3.7x and 37.9x. Its year-end P/S ranged from 1.3x to 6.6x from 2016 to 2025.
| P/S Ratio | 3.7x |
|---|---|
| Forward P/S | 3.1x |
| P/B Ratio | 37.9x |
Enterprise Valuation
Counting debt and cash, the company is valued at 58.1x EBITDA.
| EV / Sales | 4.3x |
|---|---|
| EV / EBITDA | 58.1x |
Price Statistics
The stock is down 27.63% over 52 weeks and trades 2.96% below its 50-day average.
| Beta (1Y) | 1.42 |
|---|---|
| 52-Week Change | -27.63% |
| 1-Month Change | +6.65% |
| 3-Month Change | -29.11% |
| 6-Month Change | -3.78% |
| 5-Year Change | +179.88% |
| 10-Year Change | +951.77% |
| Total Return (1Y) | -27.63% |
| Total Return (3Y CAGR) | +48.79% |
| Total Return (5Y CAGR) | +22.31% |
| Return vs SPY (1Y) | -37.26% |
| Max Drawdown (1Y) | -52.48% |
| Max Drawdown (3Y) | -61.38% |
| Sharpe Ratio (1Y) | -0.45 |
| Correlation with SPY (1Y) | 0.30 |
| 50-Day Average | $30.42 |
| 200-Day Average | $37.37 |
| 52-Week Range | $25.76 to $54.85 |
| RSI (14 Days) | 51.0 |
| Average Volume (20 Days) | 697.73K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.29x current liabilities, and total debt is 10.31x shareholder equity.
| Current Ratio | 2.29x |
|---|---|
| Quick Ratio | 2.12x |
| Debt / Equity | 10.31x |
| Debt / EBITDA | 13.11x |
| Interest Coverage | 0.96x |
Returns and Efficiency
Return on invested capital is -0.31% over the last 12 months, against a 5-year average of 2.13%.
| Return on Equity (ROE) | -97.60% |
|---|---|
| Return on Assets (ROA) | -6.43% |
| Return on Invested Capital (ROIC) | -0.31% |
| Return on Capital Employed (ROCE) | -0.31% |
| ROE (5Y Average) | -56.00% |
| ROA (5Y Average) | -8.17% |
| ROIC (5Y Average) | 2.13% |
| Asset Turnover | 0.75x |
| Inventory Turnover | 4.45x |
| Receivables Turnover | 2.21x |
| Cash Conversion Cycle | 98 days |
Scores
HROW has an Altman Z-Score of 2.07, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 2.07 |
|---|---|
| Altman Z Zone | Grey |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $303.25M over the last 12 months.
| Revenue | $303.25M |
|---|---|
| Revenue Growth (YoY) | +21.28% |
| Gross Profit | $222.94M |
| Operating Income | -$6.03M |
| Pretax Income | -$24.19M |
| Net Income | -$28.49M |
| EBITDA | $22.95M |
| EBIT | -$1.03M |
| Reported EPS (TTM) | -$0.69 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 6.59% of the $443.02M in total assets.
| Cash and Equivalents | $75.34M |
|---|---|
| Total Debt | $300.86M |
| Net Debt | $225.52M |
| Net Debt Per Share | $6.01 |
| Working Capital | $147.10M |
| Shareholder Equity | $29.19M |
| Book Value Per Share | $0.78 |
| Tangible Book Value | -$142.50M |
| Total Assets | $443.02M |
| Total Liabilities | $414.19M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.40M of capital spending, operating cash flow left -$20.35M of free cash flow.
| Operating Cash Flow | -$18.95M |
|---|---|
| Capital Expenditures | $1.40M |
| Free Cash Flow | -$20.35M |
| FCF Per Share | -$0.54 |
| Depreciation and Amortization | $23.98M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -1.99%, against a 5-year average of 4.07%.
| Gross Margin | 73.51% |
|---|---|
| Operating Margin | -1.99% |
| Pretax Margin | -7.98% |
| Net Margin | -9.39% |
| EBITDA Margin | 7.57% |
| EBIT Margin | -0.34% |
| FCF Margin | -6.71% |
| Gross Margin (5Y Average) | 73.23% |
| Operating Margin (5Y Average) | 4.07% |
| Net Margin (5Y Average) | -14.03% |
Growth
Revenue grew 45.39% a year over 3 years.
| Revenue Growth (3Y CAGR) | +45.39% |
|---|---|
| Revenue Growth (5Y CAGR) | +40.99% |
| Operating Income Growth (3Y CAGR) | +151.47% |
| Book Value Per Share Growth (2Y CAGR) | -15.57% |
Dividends and Yields
HROW does not pay a dividend. Its free cash flow yield is -1.84%.
| FCF Yield | -1.84% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-5 reverse split on Feb 8, 2013.
| Last Split Date | Feb 8, 2013 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:5 |
Peer Position
Against 12 similar companies, HROW has the 2nd highest P/S.
P/S RatioPeer median 1.8x
ROICPeer median 7.08%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +10.45%
| P/S Ratio | 3.7x vs 1.8x median |
|---|---|
| ROIC | -0.31% vs 7.08% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +21.28% vs +10.45% median |
Analyst Forecast
Consensus estimates put revenue growth at 38.72% and EPS growth at 102.17% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +38.72% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +102.17% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About HROW
What is HROW's market cap?
Harrow Health has a market cap of $1.09B. Its enterprise value, which adds debt and subtracts cash, is $1.32B.
How many shares of HROW are outstanding?
Harrow Health has 37.50M shares outstanding. The count is up 0.96% from a year earlier.
Does HROW pay a dividend?
No. Harrow Health does not pay a dividend.
How much debt does HROW have?
Harrow Health has $300.86M of total debt and $75.34M of cash and equivalents, a net debt position of $225.52M.
HROW pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors